ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Trimedat®

Its studies are mostly in Irritable Bowel Syndrome, led by Valenta Pharm JSC.

Furthest: phase 1, since Jan 15, 20261 company-led study, 1 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Valenta Pharm JSC11 open or runningphase 1since Jan 15, 2026Jan 15, 2026Dec 31, 2026phase 1 · NCT07421011

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 15, 2026First study: phase 1 study in Irritable Bowel SyndromeFirst studyNCT07421011 · 36 planned · Russia

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Irritable Bowel SyndromeNCT07421011

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07421011Irritable Bowel Syndrome · Russia1RecruitingDec 31, 202636

How it is read

Names in the registry

  • “Trimedat®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.